Novo Nordisk has filed a lawsuit against Eli Lilly, accusing the company of running misleading ads that inaccurately claim superior efficacy of Lilly's obesity and diabetes drugs compared to Novo's. The lawsuit targets ads that use outdated clinical trial data and omit new evidence about Novo's high-dose Wegovy, which offers weight loss results comparable to Lilly's drugs. Novo seeks to stop these ads and demands corrective advertising, highlighting the competitive battle in the GLP-1 drug market. The case underscores the importance of truthful advertising in helping consumers make informed treatment decisions.
Novo Nordisk maintains a Buy rating driven by strong uptake of its oral obesity drug Wegovy, which has captured 90% of the US oral obesity market with over 5 million prescriptions since launch. The company’s robust GLP-1 franchise and upcoming drug a...
Novo Nordisk remains a strong buy as it trades at a low 12.5x P/E ratio despite robust growth and expanding international operations, which now account for 65% of group growth. The company’s EUCAN obesity care segment grew 52% at constant exchange ra...
Eli Lilly shows strong performance with 48% revenue growth driven by GLP-1 drugs Mounjaro and Zepbound, raising 2026 guidance significantly. Novo Nordisk struggles with pricing cuts and pipeline setbacks, keeping its stock range-bound despite solid s...
